Fernando Rivera

25.4k total citations · 7 hit papers
168 papers, 12.9k citations indexed

About

Fernando Rivera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Fernando Rivera has authored 168 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 30 papers in Pathology and Forensic Medicine. Recurrent topics in Fernando Rivera's work include Colorectal Cancer Treatments and Studies (118 papers), Cancer Treatment and Pharmacology (51 papers) and Gastric Cancer Management and Outcomes (50 papers). Fernando Rivera is often cited by papers focused on Colorectal Cancer Treatments and Studies (118 papers), Cancer Treatment and Pharmacology (51 papers) and Gastric Cancer Management and Outcomes (50 papers). Fernando Rivera collaborates with scholars based in Spain, United States and France. Fernando Rivera's co-authors include Eduardo Díaz‐Rubio, Arié Figer, Stephen Clarke, Leonard B. Saltz, Tsai‐Shen Yang, Mikhail Lichinitser, Jim Cassidy, Werner Scheithauer, Félix Couture and Sheryl Koski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Fernando Rivera

164 papers receiving 12.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Fernando Rivera, Carsten Bokemeyer et al. profile →
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

2008 2.3k citations Leonard B. Saltz, Stephen Clarke et al. Journal of Clinical Oncology profile →
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

2008 652 citations Jim Cassidy, Stephen Clarke et al. Journal of Clinical Oncology profile →
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

2006 583 citations Arié Figer, Fernando Rivera et al. Journal of Clinical Oncology profile →
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

2022 501 citations Luis A. Díaz, Kai‐Keen Shiu et al. The Lancet Oncology profile →
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 478 citations Lee S. Schwartzberg, Fernando Rivera et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Fernando Rivera

Since Specialization

Citations

This map shows the geographic impact of Fernando Rivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Rivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Rivera more than expected).

Fields of papers citing papers by Fernando Rivera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Rivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Rivera. The network helps show where Fernando Rivera may publish in the future.

Co-authorship network of co-authors of Fernando Rivera

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Rivera. A scholar is included among the top collaborators of Fernando Rivera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Rivera. Fernando Rivera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU 2024 ·Gastroenterología y Hepatología ·Mar Riveiro‐Barciela, Sabela Carballal, Álvaro Díaz‐González, Míriam Mañosa, Javier Gállego, Joaquín Cubiella, Paula Jiménez‐Fonseca, Marı́a Varela, Luís Menchén, Bruno Sangro, Ana Fernández Montés, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María‐Carlota Londoño	7
2	LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study 2023 ·Annals of Oncology ·(unknown), Thierry André, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, C.J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, (unknown), Dung T. Le, Takayuki Yoshino, Yu Zuo, (unknown), David E. Adelberg, Luis A. Díaz	12
3	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study breakdown → 2022 ·The Lancet Oncology ·Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, (unknown), Fernando Rivera, Elena Élez, Dung T. Le, Takayuki Yoshino, (unknown), David R. Fogelman, Patricia Marinello, Thierry André	501
4	Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 2021 ·European Journal of Surgical Oncology ·Manuel Benavides, Auxiliadora Gómez‐España, Pilar García‐Alfonso, (unknown), José María Viéitez, Fernando Rivera, María José Safont, Albert Abad, Javier Sastre, Manuel Valladares‐Ayerbes, Alfredo Carrato, Encarnación González‐Flores, Luis Robles, Antonieta Salud, Vicente Alonso-Orduña, Clara Montagut, Elena Asensio, Eduardo Díaz‐Rubio, Enrique Aranda	3
5	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) 2020 ·Annals of Oncology ·Madappa N. Kundranda, Antonio Cubillo Gracián, Syed F. Zafar, (unknown), Johanna C. Bendell, Hana Algül, Fernando Rivera, Eugene R. Ahn, David Watkins, Uwe Pelzer, Veena Charu, Alena Zalutskaya, Geoffrey Kuesters, J. Marc Pipas, Sergio Santillana, Vasileios Askoxylakis, Andrew H. Ko	42
6	FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial 2020 ·ESMO Open ·Enrique Aranda, José María Viéitez, Auxiliadora Gómez‐España, (unknown), Antonieta Salud, (unknown), Pilar García‐Alfonso, Fernando Rivera, (unknown), (unknown), Encarnación González‐Flores, Mercedes Salgado Fernández, Carmen Guillén‐Ponce, Rocio García‐Carbonero, María José Safont, Adelaida La Casta, Beatriz García-Paredes, Rafael López‐López, Javier Sastre, Eduardo Díaz‐Rubio	39
7	PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER 2019 ·Value in Health ·Fernando Rivera, F. P. Antia, Teresa Macarulla, M. A. Mangues, Andrés Muñoz, (unknown), Massimo Serra	1
8	Gold glyconanoparticles coupled to listeriolysin O 91–99 peptide serve as adjuvant therapy against melanoma 2017 ·Nanoscale ·Ricardo Calderón-González, (unknown), Isabel Garcı́a, Marco Marradi, (unknown), (unknown), (unknown), (unknown), (unknown), Almudena García‐Castaño, Javier Gómez‐Román, Soledad Penadés, Fernando Rivera, Javier Freire, (unknown)	18
9	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials 2017 ·Journal of Cancer Research and Clinical Oncology ·Julien Taı̈eb, Fernando Rivera, Salvatore Siena, Meinolf Karthaus, Manuel Valladares‐Ayerbes, Javier Gállego, Michael Geißler, Reija Koukakis, Gaston Demonty, Marc Peeters	25
10	PANOVA-2: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma – Updated efficacy results 2017 ·Annals of Oncology ·Manuel Benavides, Carmen Guillén‐Ponce, Fernando Rivera, Javier Gállego, José A. López-Martín, (unknown)	1
11	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma 2017 ·International Journal of Colorectal Disease ·Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, Isabel Sevilla, Frédéric Forget, Gianpiero Fasola, Jean-Luc Canon, Xuesong Guan, Gaston Demonty, Lee S. Schwartzberg	79
12	PD-013 A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC) 2015 ·Annals of Oncology ·Volker Heinemann, Fernando Rivera, (unknown), Reija Koukakis, Jan-Henrik Terwey, Jean‐Yves Douillard	1
13	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer breakdown → 2014 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, J. Randolph Hecht, Hua Yu, Kelly S. Oliner, William Y. Go	478
14	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial 2014 ·Annals of Oncology ·Élena Elez, Ilona Kocáková, Thomas Höhler, Uwe M. Martens, Carsten Bokemeyer, Eric Van Cutsem, Bohuslav Melichar, Martin Šmakal, Tibor Csőszi, Э. Э. Топузов, Р. В. Орлова, Sergei Tjulandin, Fernando Rivera, J. Sträub, Rolf Bruns, Sonia Quaratino, Josep Tabernero	89
15	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial 2013 ·Clinical Cancer Research ·Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, (unknown), Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, (unknown), Vanessa Potter, (unknown), Nathalie A. Lokker, Peter J. O’Dwyer	69
16	Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab 2013 ·Clinical Colorectal Cancer ·Javier Sastre, Marta Vidaurreta, (unknown), Fernando Rivera, Bartomeu Massutí, (unknown), Albert Abad, Manuel Gallén, Manuel Benavides, Enrique Aranda, Eduardo Díaz‐Rubio	30
17	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC) 2013 ·Annals of Oncology ·Kelly S. Oliner, Jean‐Yves Douillard, Salvatore Siena, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, (unknown), Martin Šmakal, Richard T. Williams, Alan Rong, Jeffrey S. Wiezorek, Roger Sidhu, Scott D. Patterson	2
18	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study breakdown → 2010 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean‐Luc Canon, M. Rother, Kelly S. Oliner, Michael Wolf, Jennifer Gansert	1351
19	SAFETY AND EFFICACY OF BEVACIZUMAB (BEV) AND CHEMOTHERAPY IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE BEAT OBSERVATIONAL COHORT STUDY 2009 ·UCL Discovery (University College London) ·Eric Van Cutsem, Fernando Rivera, Sean L. Berry, (unknown), (unknown), Maria Di Bartolomeo, M. Mazier, J. R. Canon, (unknown), Marc Peeters, John Bridgewater, David Cunningham	5
20	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study breakdown → 2008 ·Journal of Clinical Oncology ·Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Jim Cassidy	2275

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact